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Abstract
The activation of group I metabotropic glutamate receptor (group I mGlus) has been shown to produce neuroprotective or
neurotoxic effects. In this study, we investigated the effects of N-acetylcysteine (NAC), a precursor of the antioxidant
glutathione, on group I mGlus activation in apoptosis of glial C6 and MN9D cell lines, and a rat model of Parkinson’s disease
(PD). We demonstrated that NAC protected against apoptosis through modulation of group I mGlus activity. In glial C6 cells,
NAC promoted phosphorylation of ERK induced by (s)-3,5- dihydroxy-phenylglycine (DHPG), an agonist of group I mGlus.
NAC enhanced the group I mGlus-mediated protection from staurosporine (STS)-induced apoptosis following DHPG
treatment. Moreover, in rotenone-treated MN9D cells and PD rat model, NAC protected against group I mGlus-induced
toxicity by compromising the decrease in phosphorylation of ERK, phosphorylation or expression level of TH. Furthermore,
the results showed that NAC prohibited the level of ROS and oxidation of cellular GSH/GSSG (Eh) accompanied by activated
group I mGlus in the experimental models. Our results suggest that NAC might act as a regulator of group I mGlus-mediated
activities in both neuroprotection and neurotoxicity via reducing the oxidative stress, eventually to protect cell survival. The
study also suggests that NAC might be a potential therapeutics targeting for group I mGlus activation in the treatment of
PD.
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Introduction
Metabotropic glutamate receptors (mGlus) are G-protein-
coupled receptors that can be classified into group I receptors
(mGlu1 and mGlu5), groups II (mGlu2 and mGlu3) and III
(mGlu4, mGlu6, mGlu7 and mGlu8), based on their signal
transduction pathways and pharmacologic profiles. Increasing
evidence has indicated roles for group I metabotropic glutamate
receptors (group I mGlus) in a variety of disorders, including
Parkinson’s disease (PD), amyotrophic lateral sclerosis, epilepsy,
stroke and Alzheimer’s disease [1]. The activation of group I
mGlus has been shown to produce neuroprotective or neurotoxic
effects in cell viabilty [2]. It is therefore of considerable interest to
investigate the regulation of group I mGlus in the context of
neuroprotection in more details.
The activation of group I mGlus can be neuroprotective or
neurotoxic effects depending on different stimuli or the molecular
mechanism by which the signaling is achieved. Activation of
group I mGlus can either exacerbate neuronal death induced by
oxygen-glucose deprivation [3] or attenuate oligodendrocyte
excitoxicity by inhibiting the accumulation of reactive oxygen
species (ROS) and intracellular glutathione (GSH) loss [4]. Group
I mGlus activation in neuroprotection initiates various intracel-
lular signaling mechanisms, including extracellular signal-regu-
lated kinase (ERK) [5–6]. Activation of the ERK pathway can be
involved in neuroprotection [7–9], or neurotoxicity [10–12].
Moreover, activation of group I mGlus is also involved in
apoptosis signaling. For example, DHPG elicited a significant
increase in poly (ADP-ribose) polymerase (PARP) activity that
was completely abolished by the administration of the mGlu1
antagonist 3-MATIDA and partially prevented by the mGlu5
antagonist MPEP [13].
Since activation of group I mGlus can be neuroprotective or
neurotoxic, it is important to understand the mechanism
responsible for modulation of the receptor activity in cell survival.
Previous study has shown that the activation of mGlus protects
nerve cells from oxidative stress [14]. We therefore wanted to test
whether group I mGlus-mediated cell survival is regulated by
NAC treatment. In the study, we investigated the effects of NAC
on the activation of group I mGlus in glial C6 and MN9D cells,
and in a rotenone-induced rat model of PD. Interestingly, we
found that NAC can protect against cell apoptosis in both
situations of neuroprotection and neurotoxicity through modulat-
ing group I mGlus-mediated ERK activity, suggesting that NAC
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receptor to be neuroprotective.
Results
NAC enhanced phospho-ERK induced by activation of
group I mGlus in glial C6 cells
Recent studies showed that group I mGlus was expressed in C6
glial cells [15] and that activation of these receptors by DHPG led
to phosphorylation of ERK, which was well characterized in the
activity of group I mGlus [16–17]. To examine the effects of NAC
on the activation of group I mGlus, we first investigated the effects
of NAC on ERK phosphorylation in response to DHPG treatment
in glial C6 cells. As shown in Fig. 1A, consistent with previous
studies [16–17], exposure of cells to DHPG promoted phospho-
ERK. NAC enhanced DHPG-induced phospho-ERK in a dose
dependent manner, and reached maximal effect at 5 mM. This
concentration was therefore used in subsequent experiments. To
confirm the role of NAC, a precursor of glutathione (GSH), in the
activation of ERK by group I mGlus, the selective GSH-depleting
agent, buthionine sulfoximine (BSO) was introduced. The
enhancement of ERK phosphorylation by NAC was partially
reversed by BSO, indicating that GSH-controlled anti-oxidative
stress was involved in the regulation of ERK phosphorylation by
group I mGlus (Fig. 1B ). It has been shown that activation of
group I mGlus was not involved in the p38 MAP kinase pathway
[17]. Consistent with DHPG treatment in the report, neither NAC
nor BSO affected the levels of phospho-p38 (Fig. 1B), suggesting
that NAC might specifically enhanced DHPG-induced ERK
phosphorylation. To examine the involvement of group I mGlus
activation and the ERK pathway in the mechanism of NAC, (RS)-
1-aminoindan-1,5-dicarboxylic acid (AIDA , an antagonist of
group I mGlus) and U0126 (an inhibitor of MEK) were applied
before DHPG application, both of which significantly attenuated
the promotion of DHPG-induced ERK phosphorylation by NAC
(Fig. 1C).
NAC enhanced group I mGlus-mediated protection
against STS toxicity in glial C6 cells
Because NAC can affect group I mGlus-mediated ERK
signaling in glial C6 cells, we further investigated its ability to
modulate cell apoptosis by affecting group I mGlus activity. Cells
were treated with the well-established stress agent, STS, which
induces apoptosis via mitochondria-dependent pathways [18–19].
Cytochrome c release, Bcl-2/Bax ratio and cleavage of PARP
were measured as markers of apoptosis. STS treatment led to a
time-dependent increase in cytochrome c release into the cytosol,
and reduction in the Bcl-2/Bax ratio and the level of uncleaved
PARP (Fig. 2A). Release of cytochrome c into the cytosol was
partly inhibited by DHPG exposure, and this effect was
strengthened by pretreatment with NAC (Fig. 2B). Moreover,
NAC promoted the DHPG-induced increase in the Bcl-2/Bax
ratio and prevented the cleavage of PARP, which could be
reversed by BSO pretreatment (Fig. 2C). We further tested the
effect of caspase-3 in NAC protection against group I mGlus-
mediated cellular apoptosis. Under the experimental conditions,
pretreatment of Z-DEVD-FMK, a specific caspase-3 inhibitor,
with DHPG application inhibited STS-induced cell death,
suggesting that caspase-3 is involved in NAC protection against
group I mGlus-mediated cellular apoptosis (Fig. S1). These results
indicate that NAC enhanced the protective effects of activated
group I mGlus against STS toxicity. The effects of NAC on
DHPG-mediated apoptosis were further examined by TUNEL
staining. As shown in Fig. 2D, STS exposure was accompanied by
an increase in the number of TUNEL-positive, apoptotic cells,
which was reduced by DHPG exposure accompanied by NAC
treatment, compared with DHPG treatment alone. Pretreatment
with BSO, the group I mGlus antagonist AIDA, or the MEK
inhibitor U0126, reversed the effects of NAC on cell apoptosis
with DHPG exposure. These results confirmed an enhanced
apoptosis-protective effect of NAC against STS toxicity via group I
mGlus-activated ERK pathway.
NAC protects against group I mGlus-induced toxicity in
rotenone-treated MN9D cells and an animal model of PD
Activation of mGlus plays a pivotal role in PD [20–21], while
mitochondrial dysfunction and oxidative stress have also been
shown to be involved [22]. Thus, we wanted to test the effect of
NAC on group I mGlus activation by DHPG and its potential role
in the process of PD.
In vitro , we treated murine dopaminergic MN9D cells with the
mitochondrial complex I inhibitor rotenone, an agent inducing
apoptosis via oxidative stress involved in mitochondria-dependent
pathways, for establishing a well-known neurotoxic model
mimicking PD. The model was confirmed by Fig. 3A, exposure
of cell cultures to rotenone decreased phospho-tyrosine hydrox-
ylase (TH), an enzyme for the rate-limiting step in the biosynthesis
of dopamine, and the phosphorylation form is active in cells [23].
PARP cleavage was increased and phosphorylation of ERK had
declined by 12 h. Interestingly, the application of DHPG
promoted the decrease in phospho-TH and further decreased
phospho-ERK and the cleavage of PARP induced by rotenone
treatment. However, these rotenone-induced effects can be
inhibited by NAC pretreatment (Fig. 3B). We also tested the
effect of caspase-3 in NAC protection against group I mGluRs-
mediated cellular apoptosis. Under the experimental conditions,
pretreatment of Z-DEVD-FMK, a specific caspase-3 inhibitor,
with DHPG application also inhibited rotenone-induced cell
death, suggesting that protection of NAC against group I mGlus-
mediated cellular apoptosis is through caspase-3 activation (Fig.
S2). Consistently, MTT assay showed that exposure of cells to
rotenone decreased cell viability by 23%, and application of
DHPG increased cell loss by an additional 18%. NAC inhibited
rotenone-induced cell death in the presence of DHPG (Fig. 3C).
The results were confirmed by using typan blue-exclusion assay to
assess cell death (Fig.3D). Collectively, the data demonstrate that
the exacerbation of rotenone-induced toxicity by group I mGlus
activation in MN9D cells was alleviated by NAC treatment.
We determined if the protective effect of NAC in vitro could be
corroborated in vivo, using a rotenone-induced rat model of PD.
In the rotarod test, all groups of animals learned the task and were
able to remain on the rod for 180 s at a speed of 5 rpm before
rotenone injection. However, as shown in Fig. 4A, the time-on-
the-rod was significantly reduced 3–4 weeks after rotenone
administration, compared with vehicle-treated rats. Furthermore,
DHPG-treated rats had a shorter time-on-the-rod, which was
prolonged by NAC pretreatment, at 4 weeks after rotenone
administration, indicating that NAC was able to alleviate the
behavioral symptoms induced by group I mGlus activation in
rotenone-treated rats. Changes in expression levels of TH in the
substantia nigra and striatum were determined by immunohistol-
ogy and Western blotting, respectively (Fig. 4B and C). A
reduction in TH expression level was observed 4 weeks after
rotenone administration, in line with the known sensitivity of
nigro-striatal dopaminergic neurons to rotenone toxicity [24–25].
DHPG administration exacerbated the rotenone-induced decrease
in TH in the lesioned substantia nigra and striatum, compared
with the intact side. NAC treatment attenuated the decline in TH
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32503Figure 1. The effect of NAC on group I mGlus activation-mediated phospho-ERK, phospho-p38 in glial C6 cells. NAC was applied to C6
glial cells for 30 min, with or without pretreatment with 100 mM BSO for 12 h, followed by DHPG 100 mM treatment for 5 min. (A) Exposure to
different concentrations of NAC enhanced DHPG-induced phospho-ERK. (B) BSO treatment partially reversed the effects of NAC on group I mGlus
activation-mediated phospho-ERK, and neither NAC nor BSO had any significant effect on phospho-p38. (C) NAC upregulated phospho-ERK
stimulated by DHPG was prevented by both group I mGlus antagonist AIDA (100 mM) and the MEK inhibitor U0126 (20 mM). Non-treated cells were
used as controls in all panels. (A, B and C) Representative immunoblots are shown above the quantitative data for pERK1/2. *p,0.05 and **p,0.01
versus control; # p,0.05, ##p,0.01.
doi:10.1371/journal.pone.0032503.g001
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treatment also attenuated the decline in ERK phosphorylation and
the Bcl-2/Bax ratio mediated by DHPG treatment followed by
rotenone treatmemt (Fig. 4D). Taken together, these results
demonstrate that NAC suppressed the effects of group I mGlus
activation by DHPG in a rotenone-induced rodent model of PD.
The effect of NAC on the oxidative stress induced by
activation of group I mGlus in glial C6 cells and rotenone-
induced models of cells and rat of PD
Antioxidant NAC, a precursor of GSH is known to scavenge
ROS, and capable of reducing oxidized proteins [26]. Resting
plasma GSH levels are lower in PD than in any other
neurological condition [27]. To further examine whether NAC
protected from apoptosis mediated by activation of group I
mGlus through regulation of oxidative stress, we tested the effect
of NAC on the intracellular ROS production and the redox
potential of GSH/GSSG (Eh) in the experimental models. The
results showed that NAC further prohibited the level of STS-
induced ROS (Fig. 5A) and oxidation of cellular GSH/GSSG
(Eh) (Fig. 5C) accompanied by activated group I mGlus in C6
cells. NAC also inhibited the level of ROS production (Fig. 5B)
and the oxidation of cellular GSH/GSSG (Eh) induced by
activated group I mGlus in rotenone-treated MN9D cells
(Fig. 5D). In addition, consistent with the report[26], plasma
GSH/GSSG (Eh) in rotenone-treated animals were observed to
be oxidized, compared with vehicle-treated group. The plasma
GSH/GSSG (Eh) induced by DHPG was further oxidized
compared to rotenone-treated animals, and NAC treatment
efficiently inhibited the oxidation of GSH/GSSG (Eh) caused by
DHPG treatment (Fig. 5E). The data suggest that NAC might
modulate group I mGlus-mediated signaling pathways to protect
from cell apoptosis by reducing the oxidative stress.
Discussion
This study investigated the relationship between group I mGlus
activation and NAC in neuroprotection in glial C6 and MN9D
cells, and in a rat model of PD. NAC demonstrated a protective
effect on DHPG-mediated group I mGlus activation in the
experimental models, via regulating group I mGlus-mediated
ERK activity, whose activation functions in cell survival [7,10]. In
glial C6 cells, NAC promoted ERK activation induced by group I
mGlus activation, however, in rotenone-treated MN9D cells, NAC
complemented the inhibitory effect of group I mGlus activation on
ERK phosphorylation. Moreover, in glial C6 cells, NAC enhanced
the effects of group I mGlus activation via inhibition of
cytochrome c release and the increases in the Bcl-2/Bax ratio
and uncleaved PARP, further inhibiting STS-induced apoptosis.
In a rotenone-treated MN9D cells and rat model of PD, treatment
with NAC suppressed the effects of group I mGlus activation by
DHPG to protect from cell death. These results revealed that
NAC protected against apoptosis through regulating the activation
of group I mGlus in both situations of neuroprotection and
neurotoxicity, indicating that NAC might act as a regulator of
group I mGlus-mediated activity to protect cell survival.
Activation of group I mGlus is involved in the survival of
neurons via control of oxidative stress and regulation of
intracellular GSH [4,14]. However, how intracellular redox
status controls group I mGlus activation remains unclear.
Previous studies have shown that the pharmacologic modulation
of mGlus can ameliorate motor abnormalities in experimental
models of PD [27–28], and blockage of mGlu5 has shown a
beneficial antidyskinetic effect in L-dopa-treated 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine ( MPTP) ) monkeys [29].
Moreover, oxidative stress to dopaminergic neurons is believed
to be one of the causes of neurodegeneration in PD. In an animal
model study, the antioxidants, NAC and L-2-oxothiazolidine-4-
carboxylate (OTC) were suggested to prevent MPTP-induced
apoptosis by suppressing JNK activation [30]. The results of our
study indicate that antioxidant NAC regulates the activity of
group I mGlus, as evidenced by changes in the activation of the
receptor-mediated ERK pathway, cell viability and apoptosis.
Furthermore, our results suggest a role for the regulation of group
I mGlus activation by NAC in the process of PD, both in
rotenone-induced cells and rat model. The modulation of NAC
on group I mGlus activation might be through regulating
intracellular GSH/GSSG (Eh) to reduce the oxidative stress
induced by rotenone and DHPG treatment (Fig. 5B and D).
Indeed, the regulation of NAC on the level of ROS and GSH/
GSSG (Eh) with activation of group I mGlus was also found in
glial C6 cells (Fig. 5A and C). In addition, NAC treatment alone
also regulated the level of ROS and GSH/GSSG (Eh) and had a
protective effect in rotenone-induced MN9D cells and animal
model; importantly, DHPG-induced oxidative stress, and subse-
quently, the relevant markers were found to be significantly
affected by NAC treatment (Figs. 3 and 4), confirming that NAC
can play a protective role in group I mGlus activation in the
current experimental models. Taken together, these results reveal
that NAC regulated the effects of group I mGlus activation on
cell viability, indicating a possible role for intracellular redox
status in the activation of group I mGlus associated with cell
survival, especially in PD model.
.
The activation of group I mGlus has been shown to produce the
relative neuroprotective or neurotoxic effects depending on
different stimuli. For example, activation of these receptors
downregulates nitric oxide-induced cysteine protease caspase-3
activity and prevents the induction of programmed cell death in
rat hippocampal neurons [31]. On the other hand, selective
Figure 2. NAC enhanced group I mGlus-mediated protection against STS toxicity in glial C6 cells. (A) Cells were treated with 1 mM STS
for the indicated time. STS treatment led to an increase in cytochrome c release into the cytosol and a fall in the Bcl-2/Bax ratio and PARP (116 kD)
level in a time-dependent manner. (B) Cells were exposed to DHPG (100 mM, 30 min) after 5 mM NAC pretreatment, followed by STS exposure
together with NAC and DHPG incubation for 9 h. Release of cytochrome c into the cytosol was partly inhibited by DHPG exposure, and further
strengthened by NAC pretreatment. A representative immunoblot is shown above the quantitative data. (C) Cells were preincubated with DHPG
(100 mM, 30 min) in the presence of either NAC or NAC/BSO, followed by STS exposure together with DHPG and NAC for 12 h. NAC promoted the
DHPG-induced increase in the Bcl-2/Bax ratio and prevented the cleavage of PARP, which could be reversed by BSO pretreatment. A representative
immunoblot is shown to the right of the quantitative data. (D) The effect of NAC on DHPG-mediated apoptosis was further examined in TUNEL
staining experiments. Cells were exposed to NAC (5 mM ) or DHPG (100 mM, 30 min) after pretreatment with BSO (100 mM), the group I mGlus
antagonist AIDA(100 mM) or the MEK inhibitor U0126 (20 mM), followed by STS exposure for 12 h. Magnification 6400 (n=4–6 microscopic fields,
100–300 glial C6 cells per field) (left). Densitometric analysis of TUNEL-positive cells, expressed as a percentage of total cells (right). *p,0.05 and
**p,0.01 versus control; #p,0.05, ## p,0.01.
doi:10.1371/journal.pone.0032503.g002
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organotypic cultures subjected to 3-nitropropionic acid (3-NP)
insult in vitro, and in a middle cerebral artery-occlusion model of
ischemia in vivo [32]. The results of these studies suggest that the
function of group I mGlus in cell viabilty varies among cell types,
potentially controlled by differential signaling pathways. Indeed,
we found that activation of group I mGlus inhibited STS-induced
apoptosis in glial C6 cells and promoted ERK activation induced
by group I mGlus activation (Figs. 1 and 2), however, in rotenone-
treated MN9D cells and rat of PD, activation of group I mGlus
promoted the cellular toxicity and inhibited ERK phosphorylation
(Figs. 3 and 4). Whereas the effects of group I mGlus activation on
cell apoptosis differed in those models, the protection of NAC
against cellular toxicity with activated group I mGlus was found
for both neuroprotective and neurotoxic situations, through
modulation of receptor-mediated activity. Our study might
provide a regulatory mechanism of group I mGlus activity in
neuroprotection by NAC treatment.
In summary, this study showed that NAC was able to protect
against apoptosis via modulating the activity of group I mGlus, in
glial C6 and MN9D cells, as well as in a rotenone-treated rat
model of PD. Additional studies are required to determine how
NAC affects the activation of group I mGlus to protect cells from
apoptosis in details. Although the mechanistic details of redox
control of group I mGlus activation remain to be fully elucidated,
this study has revealed a previously undescribed biological
Figure 3. The effect of NAC on rotenone-induced toxicity in MN9D cells. (A) Cells were treated with 50 nM rotenone for different durations
(0, 3, 6, 9 and 12 h). Representative Western blots show protein levels of phospho-ERK, phospho-TH and PARP cleavage. (B) Cells were incubated with
NAC (5 mM) and/or stimulation with DHPG (100 mM), followed by rotenone together with NAC and DHPG incubation for 12 h. Western blotting was
performed to determine phospho-ERK, phospho-TH and PARP cleavage (left). Densitometric analysis shows phospho-ERK, phospho-TH and cleaved
PARP for each condition, compared with control cultures with rotenone alone (left columns) (right). (C) MTT assay for detecting cell viability. Cells
were incubated with NAC (5 mM) and/or stimulation with DHPG (100 mM), followed by rotenone for 12 h. Non-treated cells were used as the control.
Cell viability is expressed as a percentage of control cultures (left column). (D) NAC prohibited cell death induced by group I mGlus in rotenone-
treated MN9D cells. Cells were incubated with NAC (5 mM) and/or stimulation with DHPG (100 mM) for 30 min, followed by rotenone with NAC ) and/
or DHPG incubation for 12 h. Cell death was evaluated by Typan blue-exclusion assay, and expressed as a percentage of total cells. Cells without the
treatment were as the control. *p,0.05 and **p,0.01 versus control; #p,0.05, ## p,0.01.
doi:10.1371/journal.pone.0032503.g003
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the activation of group I mGlus. These results contribute to the
understanding of the pathogenesis of PD and could aid in the
development of more effective ways to prevent dopaminergic
neuronal death. These results, together with the distribution of
group I mGlus in the brain, suggest that NAC might represent a
new treatment for a variety of neurodegenerative diseases
associated with group I mGlus.
Figure 4. The effect of NAC on rotenone-induced rat model of PD. The treatment of rats with drugs is shown in the scheme (top). (A) Results
of rotarod tests before ipsilateral rotenone injection, and 3 and 4 weeks after the injection of rotenone, shown as the length of time animals were
able to remain on the rod at 5.r.p.m. Male Sprague-Dawley rats received ipsilateral rotenone (6 mg) injection after pretreatment with NAC (33 mg/kg/
day) and DHPG (0.3 mg/kg/day) for 1 week and that the treatment has been continued until sacrifice. Time-on-the rod is expressed as a percentage
of control before rotenone injection (left column). (B) Microphotographs of TH-positive neurons in rat substantia nigra by immunohistology (left).
Magnification 65 (Scale bar, 200 mm). Cell counts of TH-positive neurons in rat substantia nigra (n=6) are also shown (right). (C) Representative
Western blot showing the level of TH in the intact (left: L) and injected (right: R) striata of animals that received ipsilateral vehicle or rotenone
injections. Densitometric analysis showing TH for each condition compared with control (left lane) (n=10/group). (D) Densitometric analysis showing
phospho-ERK and Bcl-2/Bax ratio in the striatum of animals for each condition compared with control (left lane). (E) NAC inhibited the oxidation of
cellular GSH/GSSG (Eh) induced by activated group I mGlus in rotenone-treated rat model of PD. *p,0.05 and **p,0.01 versus control; #p,0.05,
## p,0.01.
doi:10.1371/journal.pone.0032503.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32503Figure 5. The effect of NAC on the oxidative stress induced by activation of group I mGlus in glial C6 cells and rotenone-treated
models of cells and rat of PD. (A) NAC further prohibited the level of STS-induced ROS accompanied by activated group I mGlus in C6 cells. Cells
were exposed to DHPG (100 mM, 30 min) after 5 mM NAC pretreatment, followed by STS exposure with NAC and DHPG incubation for 9 h and
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Materials
DMEM/F-12 (1:1; Gibco, USA), Dulbecco’s modified eagle
medium (DMEM) and fetal bovine serum were purchased from
Hyclone (USA); U0126 (MAPK-ERK kinase (MEK) inhibitor),
DHPG (a group I mGlus agonist); and (RS)-1-aminoindan-1,5-
dicarboxylic acid (AIDA, a group I mGlus antagonist) were from
Tocris Biosciences (UK); Z-DEVD-FMK (an irreversible and cell
permeable inhibitor of caspase-3) was purchased from Becton,
Dickinson and Company (BD, USA). NAC, buthionine sulfox-
imine (BSO) and staurosporine (STS) were obtained from Sigma
(USA).
Cell culture and Treatment
Rat C6 glial cells were obtained from the Institute of Cell
Biology, Chinese Academy of Sciences (Shanghai, China) and
maintained in complete medium (DMEM plus 10% fet al bovine
serum and 1% penicillin/streptomycin) at 37uC in a 5% CO2
incubator. The MN9D dopaminergic neuronal cells were a
generous gift from professor Hui Yang (Capital Medical
University, Beijing, China) and were cultivated in complete
medium (DMEM/F-12 plus 10% fet al bovine serum and 1%
penicillin/streptomycin).
To stimulate or inhibit receptors, cell cultures were treated with
either DHPG 100 mM for 5 min, or AIDA 10 mM for 30 min. To
block the ERK pathway, cell cultures were preincubated with
U0126 10 mM for 30 min before stimulation. STS and rotenone
were prepared as 1 mM and 50 mM stock solutions, respectively,
dissolved in dimethylsulfoxide (DMSO) and stored at 280uC until
use. For treatments, STS and rotenone stock solutions were diluted
with medium to 1 mM and 50 nM, respectively, and added to the
cells.
Protein analysis and Western blotting
After appropriate treatments, cells were lysed in lysis buffer
(final concentration: 50 mM Tris (pH 8.0), 50 mM NaCl, 1%
Nonidet P-40, 20 nM okadaic acid, 20 mM sodium orthovana-
date, phosphatase inhibitor mixture (Pierce,USA), and protease
inhibitor mixture (Pierce)). Protein concentrations were deter-
mined using a BCA assay kit (Pierce). Immunoblot analysis was
performed using equal amounts of protein for each sample
loaded onto 8% or 12% sodium dodecyl sulfate-polyacrylamide
gels. Proteins were then transferred onto immobilon-P transfer
membranes (Millipore, USA). Membranes were blocked for 1 h
with 5% milk in TBST (20 mM Tris-HCl, pH 7.6, 137 mM
NaCl, 0.05% Tween 20), followed by incubation with the
indicated antibodies overnight. The blots were then rinsed with
TBST and incubated with appropriate horseradish peroxidase
(HRP)-conjugated secondary antibodies (Cell Signaling Tech-
nology, USA) for 1 h at room temperature, rinsed with TBST
several times, and developed using a enhanced chemilumines-
cence (Applygen, China). The following antibodies were used for
Western blotting: phospho-p38 mitogen-activated protein kinase
(MAPK) (Thr180/Tyr182; #9211), p38 MAPK rabbit poly-
clonal antibody (#9212), PARP rabbit polyclonal antibody
(#9542) and b-actin rabbit polyclonal antibody (#4967),
cytochrome c rabbit polyclonal antibody (#4272), Bcl-2 rabbit
polyclonal antibody (#2876), Bax rabbit polyclonal antibody
(#2772), tyrosine hydroxylase (TH) rabbit polyclonal antibody
(#2792), phospho-TH rabbit polyclonal antibody (Ser40;
#2791), a-tubulin mouse polyclonal antibody (#3873) (all from
Cell Signaling). Phospho-ERK1/2 rabbit monoclonal antibody
(#05-797R) and ERK1/2 rabbit polyclonal antibody (#06-182)
were from Millipore.
Analysis of Cytosolic Cytochrome c Accumulation
Glial C6 cells were grown to 80% confluence in 10-cm diameter
dishes. Cytochrome c release from mitochondria into the cytosol
was measured by Western blot analysis. In brief, treated cells were
washed twice with chilled PBS followed by the addition of 1 ml
Mito-Cyto Buffer (Mitochondria/ Cytosol Kit, Applygen Tech-
nologies, China). After incubation on ice for 5 min, the cells were
gently scraped off, ground 30–40 times and centrifuged at 800 g
for 5 min at 4uC. The supernatants were further centrifuged at
12,000 g for 10 min at 4uC. The supernatant was collected as a
cytosolic fraction and subjected to Western blot analysis, as
described above.
Cell viability, Apoptosis and Trypan blue-exclusion assay
The viability of MN9D cells was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say. Briefly, cells cultured on 96-well plates were incubated for 4 h
at 37uC with 0.5 mg/ml MTT (Sigma). The formation of the
formazan product, proportional to the number of viable cells, was
measured colorimetrically at 490 nm, and the background was
measured at 650nm after extraction with 100 ml DMSO (Sigma).
Terminal deoxynucleotidyl transferase mediated dUTP-biotin
nick-end labeling (TUNEL) staining was performed using a In
Situ Cell Death Detection kit (Roche Applied Science, Germany).
Briefly, glial C6 cells grown on glass coverslips were fixed with 4%
paraformaldehyde and permeabilized with 0.1% Triton X-100,
and processed for TUNEL staining (green/red). Hoechst stain
(Sigma) was added to counterstain nuclei. Photomicrographs from
4–6 different fields in each coverslip were captured. Typically,
100–200 cells were analyzed to determine the number of TUNEL-
positive (apoptotic) cells. Total numbers of neurons were identified
by Hoechst staining (blue). Apoptotic cell numbers were presented
as a percentage of TUNEL-positive cells in relation to total cell
numbers. For trypan blue-exclusion assay, briefly, treated cells
were stained with 4% trypan blue (Sigma, USA) solution for 5min,
and assessed for cell death by counting viable (nonstained) and
non-viable (blue) cells. Cell death is expressed as the percentage of
non-viable cells to the total number of cells counted. Eight
examined for cellular ROS measured by dichlorofluorescein (DCF) assay. Results are expressed as fold of control (left column). (B) NAC prohibited ROS
production induced by activated group I mGlus in rotenone-treated MN9D cells. Cells were incubated with NAC (5 mM) and/or stimulation with
DHPG (100 mM) for 30 min, followed by rotenone with NAC and /or DHPG for 9 h. Cells were detected for cellular ROS by DCF assay. The results are
expressed as fold of control (left column). (C) NAC further prohibited the STS-induced oxidation of cellular GSH/GSSG (Eh) accompanied by group I
mGlus in glial C6 cells. Cells were exposed to DHPG (100 mM, 30 min) after 5 mM NAC pretreatment, followed by STS exposure with NAC and DHPG
incubation for 9 h and examined for HPLC analysis of GSH and GSSG.. GSH/GSSG (Eh) calculated from the GSH and GSSG concentrations using the
Nernst equation. (D) NAC inhibited the oxidation of cellular GSH/GSSG (Eh) induced by activated group I mGlus in rotenone-treated MN9D cells. Cells
were incubated with NAC (5 mM) and/or stimulation with DHPG (100 mM) for 30 min, followed by rotenone with NAC and DHPG incubation for 9 h.
Cells were then examined for GSH/GSSG (Eh). (E) NAC inhibited the oxidation of cellular GSH/GSSG (Eh) induced by activated group I mGlus in
rotenone-treated rat model of PD. Cells without treatment were used as controls. *p,0.05 versus control; # p,0.05.
doi:10.1371/journal.pone.0032503.g005
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trypan blue staining.
Animals and Treatments
Male Sprague-Dawley rats (190–210 g) were used. Three rats
were kept in each cage under standard laboratory conditions, with
free access to standard laboratory food and tap water, a constant
room temperature of 22uC, 50–60% humidity, and a natural day-
night cycle. All procedures were approved by and performed in
accordance with the Animal Care and Use Committee of Capital
Medical University, Beijing, China (2006-0009). The investigation
conformed to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health (NIH,
1996).
Rats were anesthetized by injection of chloral hydrate (150 mg/
kg, intraperitoneally), and positioned in a stereotaxic apparatus
(Lee. Y. M et al., 2008; Weng et al., 2007). Briefly, rats received a
unilateral injection of (6 mg) rotenone in DMSO into the right
medial forebrain bundle area, at a rate of 1 ml/min, using the
coordinates 4.4-mm caudal and 1.1-mm lateral to the bregma, at a
depth of 7.9 mm from the dural surface. After injection, the needle
was left in place for an additional 10 min before slow retraction.
Animals treated with DMSO alone were used as controls.
Rats were randomly divided into five groups. Control group of rats
(n=12) received vehicle only. One group of rats (n=16) received
ipsilateral rotenone (6 mg) injection. One group of rats (n=16)
received rotenone injection after DHPG administration (0.3 mg/kg/
day, subcutaneously). One group of rats (n=16) received rotenone
(6 mg) injection after treatment with NAC (33 mg/kg/day) and
DHPG treatment, and one group of rats ((n=16) received rotenone
injection after treatment with NAC. The treatment for the group has
been continued until sacrifice. Some rats in the rotenone group died
(20%) after rotenone injection, leaving10–12 animals per group. Rats
were killed by decapitation 4 weeks after rotenone administration.
Brains were removed and sliced using a tissue chopper. Samples from
the various brain regions were collected by microdissection on a cold
plate under a stereomicroscope. Total protein samples for Western
blotting analysis were prepared by immediately freezing the tissues in
dry ice and keeping them in a deep freeze until use. They were then
homogenized in lysis buffer and total protein concentrations were
determined by BCA assay.
Behavioral Tests
The rotarod test was performed to evaluate the effects of DHPG
and NAC on rotenone-induced Parkinsonian symptoms. All rats
were tested at three time points: before administration, and 3 and
4 weeks after treatment. Only rats that completed all 4 weeks of
the experiments were included in statistical analyses. The basic
equipment consisted of a rotating roller (or rotarod) of the
appropriate diameter (8 cm) for rats, a power source for turning
the roller (control of rod speed), and four circular separators placed
along the rod at suitable intervals to divide the roller into equal-
sized compartments for simultaneous testing of four animals. Rats
were placed on the rod and tested at a speed of 5 r.p.m for a
maximum of 300 s. The length of time that each animal was able
to stay on the rod was recorded.
Immunohistochemistry
Animals were anesthetized with chloral hydrate and perfusion-
fixed through the heart with 4% paraformaldehyde in 0.1 mM
phosphate buffer pH 7.4. Brains were removed, post-fixed
overnight in the same fixative and washed sequentially in buffered
15% and 30% sucrose until they sank. Sections were cut at 20 mm
thickness using a freezing microtome, permeabilized for 15 min
with PBS containing 0.5% Triton X-100 (Sigma), followed by
30 min incubation in methanol containing 3% H2O2 to quench
endogenous peroxidase activity. Subsequently, sections were
incubated for 30 min in PBS containing 5% BSA to block non-
specific binding sites. For immunohistochemical localization of
TH, we used a monoclonal anti-TH antibody at a dilution of
1:10,000 (Sigma). Antibody exposure was performed overnight in
a cold room, followed by 30 min incubation with a HRP-linked
secondary antibody (Cell Signaling Technology), and the immu-
noreaction was visualized using diaminobenzidine tetrahy-
drochloride as a chromogen (Golden Bridge Biological Technol-
ogy, China).
Fluorescence-based Detection of Cellular ROS
Briefly, treated cells were loaded with 29,79-dichlorodihydro-
fluorescein diacetate (H2DCFDA, Sigma,USA) in loading medium
(DMEM with 1% FBS) for 30 min. The medium were removed
and cells were washed with phosphate-buffered saline (PBS).
Fluorescence (488 nm excitation and 530 nm emission) was
measured after 30 min in a microplate fluorometer (Thermo,
USA). The value obtained for a blank well with only PBS was
subtracted as the background optical density.
High performance Liquid chromatography (HPLC)
Analysis of GSH/GSSG Redox Potential (Eh) of Cells and
Plasma
The method has been described elsewhere ((Corinna et al.,
2007, Smita et al, 2009). To measure cellular GSH/GSSG (Eh),
cells were washed once with 1 ml of PBS and immediately treated
with 500 ml of ice-cold 5% (wt/vol) perchloric acid solution
containing 0.2 M boric acid and10 mM c-Glu-Glu and placed on
ice. After 5 min, cells were scraped and transferred into
microcentrifuge tubes. Samples were stored at 220uC until
derivatization with iodoacetic acid and dansyl chloride. For
HPLC analysis, derivatized samples were centrifuged, and 20 mlo f
the aqueous layer was applied to the Supelcosil LC-NH2 column
(25 cm64.6 mm; Supelco, Bellefonte, PA). Derivatives were
separated with a sodium acetate gradient in methanol-water and
detected by fluorescence. Concentrations of thiols and disulfides
were determined by integration relative to the internal standard.
The redox states of the GSH/GSSG (Eh) were calculated from
concentrations of GSH and GSSG in molar units with the
following forms of the Nernst equation for pH 7.4: GSH/
GSSG(Eh)=2264+30log([GSSG]/[GSH]
2).
To measure plasma GSH/GSSG (Eh), derivatized blood
samples were centrifuged, and 50 ml of the aqueous layer was
applied to the Supercosil LC-NH2 column. Derivatives were
separated with a sodium acetate gradient in methanol/water and
detected by fluorescence. Concentrations of thiols and disulfides
were determined by integration relative to the internal standard.
Redox potentials (Eh) of the GSH/GSSG, given in millivolts (mV),
were calculated as the above.
Statistical Analysis
All values are means6SEM. The significance of the difference
between control and samples treated with various drugs was
determined by one-way ANOVA followed by the post hoc least
significant difference test. Differences were considered significant
at p,0.05.
Supporting Information
Figure S1 Caspase-3 is involved in NAC protection from
group I mGlus-mediated apoptosis in STS-treated glial
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(100 mM, 30 min) after pretreatment with the caspase-3 inhibitor
Z-DEVD-FMK (50 mM, 1h), followed by STS exposure for 12 h.
The effect of caspase-3 was examined in TUNEL staining
experiments. Magnification 6400 (n=4–6 microscopic fields).
(B) Densitometric analysis of TUNEL-positive cells, expressed as a
percentage of total cells. #p,0.05.
(TIF)
Figure S2 Caspase-3 is involved in NAC protection from
group I mGlus-mediated apoptosis in rotenone-treated
MN9D cells. (A) Cells were exposed to NAC (5 mM ) and
DHPG (100 mM, 30 min) after pretreatment with the caspase-3
inhibitor Z-DEVD-FMK (50 mM, 1h), followed by rotenone
exposure for 12 h. The effect of caspase-3 was examined in
TUNEL staining experiments. Magnification 6400 (n=4–6
microscopic fields). (B) Densitometric analysis of TUNEL-positive
cells, expressed as a percentage of total cells. #p,0.05.
(TIF)
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